The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta

Stopped early

Conditions studied: Pregnancy Related, Trauma, Abruptio Placentae

In brief

The purpose of this study is to determine if the presence of fetal fibronectin in the cervicovaginal secretions of pregnant patients with minor maternal trauma predicts impending preterm delivery due to abruptio placenta.

Key facts

Study ID

NCT01279369

Run by

Winthrop University Hospital

People needed

3

Starts

2009-10-01

Expected to finish

2012-10-01

Last updated by the study team

2018-05-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Singleton intrauterine pregnancy ≥20 weeks and ≤35 weeks gestational age
• Chief complaint of minor maternal trauma including motor vehicle accident, patient fall or assault with absence of maternal conditions outlined in exclusion criteria

You may not qualify if…

• Maternal shock
• Unstable vital signs
• Altered sensorium
• Head injury resulting in coma
• signs or symptoms of intraperitoneal bleeding
• Emergency laparotomy for fetal or maternal indications
• Bone fractures
• History of previous abruptio placenta
• Known or suspected placenta previa
• Rupture of membranes
• Multiple gestation
• Advanced cervical dilatation ≥3cm
• Non-reassuring fetal status requiring intervention
• Vaginal bleeding on presentation
• History of intercourse and/or digital vaginal exam and/or vaginal ultrasound ≤24 hours prior to presentation
• Illicit drug use

Where it is running

• Winthrop University Hospital — Mineola, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.